Twenty-year industry veteran to lead development, execution of MMRF research strategy

The Multiple Myeloma Research Foundation (MMRF) has appointed George Mulligan, Ph.D., as its new Chief Scientific Officer effective immediately. In this role, Dr. Mulligan will lead the development, execution, and communication of the MMRF’s overall research strategy to drive clinically meaningful scientific advances for myeloma patients.

Dr. Mulligan brings to the MMRF more than 20 years of diverse experience in drug development, translational, and clinical research across the biotech and pharmaceutical industry, including extensive research in the myeloma space. His previous roles include serving as the Chief Scientific Officer at Mitobridge where he drove the overall scientific and translational strategy for its mitochondrial platform and clinical compounds. Dr. Mulligan was also Senior Director of Translational Medicine at Millennium/Takeda, leading much of its biomarker and translational research strategy for the myeloma treatment Velcade (bortezomib), and driving early genomics research that helped initiate pivotal initiatives such as the MMRF’s CoMMpass Study—the most comprehensive longitudinal genomic study ever conducted in myeloma.

“We are thrilled to have Dr. Mulligan join our team as Chief Scientific Officer,” said Michael Andreini, President and CEO, the MMRF. “He brings a wealth of myeloma-focused experience in translational and clinical research to the MMRF, and a tremendous amount of enthusiasm and passion for our mission to accelerate cures for patients. The knowledge, insight, and commitment he brings to the table will be instrumental in driving our research strategy forward on behalf of the myeloma community.”

As a member of the MMRF leadership team, Dr. Mulligan will contribute to all aspects of the MMRF and its subsidiary companies, the Multiple Myeloma Research Consortium (MMRC) and the Myeloma Investment Fund (MIF), to accelerate the development of next-generation therapies, drive research to deliver more precise and personalized treatment approaches, and empower patients with information and resources to extend their lives.

“I feel fortunate to help lead the MMRF in our urgent pursuit of a cure for each and every myeloma patient,” said Dr. Mulligan. “Since the MMRF was founded, there has been so much progress to advance new therapies for myeloma—but more clinical and translational research needs to be done. We will continue to urgently build on this legacy through our innovative and collaborative research programs until we reach our goal of a cure for every patient.”

To learn more about the MMRF and its mission, visit www.themmrf.org.

About the Multiple Myeloma Research Foundation (MMRF)

A pioneer in precision medicine, the Multiple Myeloma Research Foundation (MMRF) seeks to find a cure for all multiple myeloma patients by relentlessly pursuing innovations that accelerate the development of precision treatments for cancer. Founded in 1998 by Kathy Giusti, a multiple myeloma patient, and her twin sister Karen Andrews as a 501(c)(3) nonprofit organization, the MMRF has created the business model around cancer—from data to analytics to the clinic. The MMRF identifies barriers and then finds the solutions to overcome them, bringing in the best partners and aligning incentives in the industry to drive better outcomes for patients. Since its inception, the organization has collected thousands of samples and tissues, opened nearly 100 trials, helped bring 14 FDA-approved therapies to market, and built CoMMpass, the single largest genomic dataset for any cancer. Today, the MMRF is building on its legacy in genomics and is expanding into immunotherapy, as the combination of these two fields will be critical to making precision medicine possible for all patients. The MMRF has raised nearly $500 million and directs nearly 90% of the total funds to research and related programs. To learn more, visit www.themmrf.org.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220330005638/en/